Select Medical Holdings Taken Private in Buyout
What happened
Specialty care provider Select Medical Holdings is being acquired and taken private by a consortium led by its co-founders and private equity firm WCAS. The deal continues the trend of consolidation in the post-acute and specialty provider space.
Why it matters
The transaction values Select Medical at a $3.9 billion enterprise value, with the consortium paying $16.50 per share in cash. This price represents an 18% premium over the share price from November 24, 2025, the day before co-founder Robert Ortenzio initially submitted a proposal to the board. The deal is expected to close by mid-2026, at which point Select Medical will be delisted from the New York Stock Exchange. Co-founders Robert A. Ortenzio (Executive Chairman) and Martin F. Jackson (Senior EVP) are rolling their existing equity into the new private entity rather than taking a cash payout. They are joined by Welsh, Carson, Anderson & Stowe (WCAS), a private equity firm with a long history of healthcare investments, having invested over $11 billion in more than 100 healthcare companies. Current Select Medical management is expected to remain in place post-merger, ensuring operational continuity. Select Medical operates a significant national footprint, including 104 critical illness recovery hospitals, 38 rehabilitation hospitals, and 1,917 outpatient rehabilitation clinics across 39 states as of the end of 2025. Despite revenue growth to $5.45 billion over the last twelve months, the company has faced financial headwinds, including declining operating margins over the past five years and a high debt-to-equity ratio. Taking the company private allows for strategic changes away from the short-term pressures of public market quarterly earnings. Private equity ownership often focuses on operational streamlining and value creation for a future sale or IPO. For a provider of Select Medical's scale, this could signal upcoming changes in capital expenditures, vendor contracts, and a re-evaluation of internal systems to improve efficiency and profitability.
Key numbers
- The transaction values Select Medical at a $3.9 billion enterprise value, with the consortium paying $16.50 per share in cash.
- This price represents an 18% premium over the share price from November 24, 2025, the day before co-founder Robert Ortenzio initially submitted a proposal to the board.
- The deal is expected to close by mid-2026, at which point Select Medical will be delisted from the New York Stock Exchange.
- They are joined by Welsh, Carson, Anderson & Stowe (WCAS), a private equity firm with a long history of healthcare investments, having invested over $11 billion in more than 100 healthcare companies.
What happens next
- The deal is expected to close by mid-2026, at which point Select Medical will be delisted from the New York Stock Exchange.
- Current Select Medical management is expected to remain in place post-merger, ensuring operational continuity.
- For a provider of Select Medical's scale, this could signal upcoming changes in capital expenditures, vendor contracts, and a re-evaluation of internal systems to improve efficiency and profitability.
Quick answers
What happened in Select Medical Holdings Taken Private in Buyout?
Specialty care provider Select Medical Holdings is being acquired and taken private by a consortium led by its co-founders and private equity firm WCAS. The deal continues the trend of consolidation in the post-acute and specialty provider space.
Why does Select Medical Holdings Taken Private in Buyout matter?
The transaction values Select Medical at a $3.9 billion enterprise value, with the consortium paying $16.50 per share in cash. This price represents an 18% premium over the share price from November 24, 2025, the day before co-founder Robert Ortenzio initially submitted a proposal to the board. The deal is expected to close by mid-2026, at which point Select Medical will be delisted from the New York Stock Exchange. Co-founders Robert A. Ortenzio (Executive Chairman) and Martin F. Jackson (Senior EVP) are rolling their existing equity into the new private entity rather than taking a cash payout. They are joined by Welsh, Carson, Anderson & Stowe (WCAS), a private equity firm with a long history of healthcare investments, having invested over $11 billion in more than 100 healthcare companies. Current Select Medical management is expected to remain in place post-merger, ensuring operational continuity. Select Medical operates a significant national footprint, including 104 critical illness recovery hospitals, 38 rehabilitation hospitals, and 1,917 outpatient rehabilitation clinics across 39 states as of the end of 2025. Despite revenue growth to $5.45 billion over the last twelve months, the company has faced financial headwinds, including declining operating margins over the past five years and a high debt-to-equity ratio. Taking the company private allows for strategic changes away from the short-term pressures of public market quarterly earnings. Private equity ownership often focuses on operational streamlining and value creation for a future sale or IPO. For a provider of Select Medical's scale, this could signal upcoming changes in capital expenditures, vendor contracts, and a re-evaluation of internal systems to improve efficiency and profitability.
